TNF-Alpha inhibitors in inflammatory diseases: A Brief Review
Introduction:
Tumor Necrosis Factor-alpha (TNF-alpha) is a biologically active protein that exists as a 26 kDa membrane-bound precursor (mTNF-α). Upon cleavage by TNF-α converting enzyme (TACE), it is released as a soluble 17 kDa protein. These proteins bind to the widely expressed TNF-α receptors 1 and 2, forming biologically active homotrimers.
Without internalizing the complex, this receptor-ligand interaction triggers intracellular signaling, leading to the phosphorylation of IkBα. This activates the nuclear factor-κB (p50-p65) heterodimer, which interacts with DNA chromatin to upregulate the transcription of pro-inflammatory genes such as IL-1β, IL-6, and IL-8.
It is a cytokine produced by immune cells, primarily macrophages and T-cells. It plays a crucial role in the regulation of inflammation, immunity, and cell death. However, excessive or uncontrolled production of TNF-alpha can lead to chronic inflammation and contribute to the development and progression of various inflammatory diseases.
Inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), and ankylosing spondylitis, are all characterized by an overactive immune response and chronic inflammation. In these conditions, TNF-alpha plays a central role by promoting the release of other pro-inflammatory molecules like (Interleukin-1 (IL-1),Interleukin-6 (IL-6),Interleukin-8 (IL-8),Interleukin-12 (IL-12),Interferon-gamma (IFN-γ),Prostaglandins, including prostaglandin E2 (PGE2),Chemokines, such as monocyte chemoattractant protein-1 (MCP-1),Matrix metalloproteinases (MMPs), Adhesion molecules, like vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), activation of immune cells, and recruitment of inflammatory cells to the affected tissues. This leads to tissue damage, pain, and functional impairment.
Inhibiting TNF-alpha has emerged as an effective therapeutic strategy for managing these inflammatory diseases. TNF-alpha inhibitors, also known as anti-TNF alpha drugs, are biologic agents that specifically target and neutralize TNF-alpha, thereby reducing inflammation and disease activity. By blocking the action of TNF-alpha, these inhibitors help to modulate the immune response, suppress the production of other pro-inflammatory cytokines, improve symptoms, prevent joint destruction, promote tissue healing, and enhance overall quality of life for patients.
The importance of inhibiting TNF-alpha lies in its significant impact on the pathogenesis and progression of inflammatory diseases. Numerous clinical trials and real-world evidence have demonstrated the efficacy and safety of TNF-alpha inhibitors in reducing disease activity, improving clinical outcomes, and slowing down disease progression in patients. These agents have revolutionized the treatment landscape for inflammatory diseases, offering new therapeutic options for patients who do not respond adequately to conventional therapies.
Figure 1 : General tumor necrosis factor alpha (TNF-α) signaling pathway of TNFR1 and TNFR2. The TNFR1 signaling pathway is activated by the ligation of sTNF-α and tmTNF-α, and the death domain of TNFR1 recruits TRADD. Complex I activates NF-κB and MAPKs, which results in inflammation, tissue degeneration, host defence, cell proliferation, and cell survival. Complexes IIa and IIb activate caspase-8 and induce apoptosis. Complex IIc is known to induce necroptosis and inflammation via the activation of MLKL. The TNFR2 signaling pathway is mainly activated by tmTNF-α. TNFR2 does not possess a death domain and recruits TRAF via its TRAF domain, which activates the formation of complex I, resulting in NF-κB and MAPKs and AKT activation. TNFR2 activation is associated with homeostatic bioactivities such as tissue regeneration, cell proliferation, and cell survival, as well as host defence and inflammation.
Monoclonal antibody drugs as Anti-TNF alpha agents and their Mechanism of Action
Monoclonal antibody drugs target TNF-alpha, known as TNF inhibitors, are designed to specifically inhibit the activity of TNF-alpha, thereby reducing inflammation and alleviating symptoms.
The mechanism of action of monoclonal antibody drugs targeting TNF-alpha involves blocking the interaction between TNF-alpha and its receptors on immune cells, preventing it from interacting with its receptors, TNF-R1 and TNF-R2. This blocks the downstream signaling pathways that lead to inflammation. Anti-TNF-α mAbs can also induce apoptosis (programmed cell death) in inflammatory cells such as macrophages and neutrophils, which helps to reduce the number of inflammatory cells at the site of inflammation. Additionally, anti-TNF-α mAbs can modulate the production of other pro-inflammatory cytokines, such as IL-1β, IL-6, and IL-8, which further helps to reduce the inflammatory response.
There are several monoclonal antibody drugs that target TNF-alpha – including adalimumab, infliximab, etanercept, certolizumab pegol, and golimumab.
Recent research and advances in TNF-alpha inhibition
Researchers continue to investigate new approaches to TNF-alpha inhibition to optimize therapeutic strategies. Some recent advances include:
Bispecific Antibodies: These unique antibodies target both TNF-alpha and other proinflammatory cytokines, such as IL-17A or IL-23. In preclinical studies, bispecific antibodies have demonstrated improved efficacy and offer a more targeted and potent approach to treating inflammatory diseases.
Small Molecule Inhibitors: Researchers are developing small molecules that can penetrate cells and inhibit intracellular signaling pathways involved in TNF-alpha production and activity. Several small molecule inhibitors are currently in clinical trials, holding promise as alternative TNF-alpha inhibition strategies.
Combination therapies: Several combination therapies involving TNF-α inhibitors and other drugs to treat different disease types are both in research phases as well as clinical trial phases. Some of these drugs include Janus kinase inhibitors, phosphodiesterase inhibitors, and sphingosine-1-phosphate receptor modulators.
Future outlook
The future of TNF-alpha inhibition looks promising, with ongoing research exploring novel avenues for its application.
TNF-alpha inhibitors may find applications beyond their current approved diseases, such as neurological disorders and certain cancers. These emerging areas of research may offer new opportunities for utilizing TNF-alpha inhibition to improve patient outcomes.
As research in this area continues to evolve, it is likely that TNF-α inhibitors will be indicated for a broader range of diseases. One example is the use of TNF-α inhibitors in the treatment of hidradenitis suppurativa, a chronic inflammatory skin disease. In addition, ongoing research is exploring the potential of using TNF-α inhibitors as a treatment for diseases such as Alzheimer’s disease, depression, and multiple sclerosis.
Researchers are also working towards developing improved targeting strategies that maximize therapeutic efficacy while minimizing side effects. Advances in targeted drug delivery systems and personalized medicine approaches may enhance the precision of TNF-alpha inhibition.
Conclusion:
The study and development of TNF-alpha inhibitors represent a remarkable breakthrough in the management of inflammatory diseases. By targeting the root cause of chronic inflammation, these medications offer new hope for patients who have not responded to conventional treatments. Continued research into these inhibitors, including efforts to improve their safety and effectiveness, is vital to advancing the treatment of autoimmune and inflammatory conditions. As we gain a deeper understanding of their mechanisms, we inch closer to better managing and ultimately finding cures for these challenging diseases.
Krishgen provides a wide range of mAb drug assays for PK and ADA studies, as well as a comprehensive range of cytokine ELISA include human, mouse and rat tnf alpha, various interleukins and several other markers across 10+ species. KRIBIOLISA kits can be used for the accurate quantification of drug levels as well as anti-drug antibody levels in serum and plasma.
TNF Alpha Inhibitor Drug ELISA available with Krishgen:
TNF Alpha Inhibitor Anti-Drug Antibody ELISA available with Krishgen:
Learn more about how Krishgen ELISA is validated here.
References:
Miossec P. Update on Tumor Necrosis Factor Alpha Targeting in Rheumatoid Arthritis. Joint Bone Spine. 2019;86(6):751-754. doi:10.1016/j.jbspin.2019.08.002
Papoutsaki M, Costanzo A, Mathes EF, et al. Tumor necrosis factor circulating levels in patients with cutaneous lupus erythematosus. J Am Acad Dermatol. 2018;78(5):953-959.e2. doi:10.1016/j.jaad.2017.12.026
Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases. Retrieved from https://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-induction-of-antibodies-autoantibodies-and-autoimmune-diseases ↩ ↩2 ↩3
Understanding How Monoclonal Antibodies Work – StatPearls – NCBI Bookshelf. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK572118/ ↩ ↩2 ↩3
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023-2038.
Leonardi CL et al. Adalimumab for treatment of plaque psoriasis. N Engl J Med. 2003 Feb 13;348(7):601-8.
Weinblatt ME. Etanercept treatment of rheumatoid arthritis. Ann Rheum Dis. 1999 Jan;58(Suppl 1):I60-7.
Paulissen SMJ et al. Small-molecule inhibitors of TNF-alpha: paving the road for pulmonary drug discovery. Drug Discov Today. 2020 Jul;25(7):1151-1165.
Gerasimos Evangelatos, Giorgos Bamias, George D. Kitas, George Kollias & Petros P. Sfikakis
The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era
Rheumatology International volume 42, pages1493–1511 (2022)
Korean J Urol. 2012 Jul; 53(7): 472–477.
Tumor Necrosis Factor Inhibitors, StatPearls
Valerie Gerriets; Amandeep Goyal; Karam Khaddour
https://medlineplus.gov/druginfo/meds/a602019.html
Selection of a Biosafety Level 1 (BSL-1) surrogate to evaluate surface disinfection efficacy in Ebola outbreaks: Comparison of four bacteriophages, PLoS One. 2017; 12(5): e0177943.
Karin Gallandat* and Daniele Lantagne.
